NCT06943755
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06943755
Title Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors (STELLAR-311)
Acronym STELLAR-311
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Exelixis
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
Exelixis Clinical Site #12 RECRUITING Santa Monica California 90404 United States Details
Exelixis Clinical Site #11 RECRUITING Tampa Florida 33612 United States Details
Exelixis Clinical Site #9 RECRUITING Lexington Kentucky 40536 United States Details
Exelixis Clinical Site #8 RECRUITING Boston Massachusetts 02215 United States Details
Exelixis Clinical Site #1 RECRUITING Grand Rapids Michigan 49546 United States Details
Exelixis Clinical Site #5 RECRUITING St Louis Missouri 63110 United States Details
Exelixis Clinical Site #14 RECRUITING Albuquerque New Mexico 87131 United States Details
Exelixis Clinical Site #7 RECRUITING New York New York 10029 United States Details
Exelixis Clinical Site #6 RECRUITING Durham North Carolina 27710 United States Details
Exelixis Clinical Site #10 RECRUITING Grapevine Texas 76051 United States Details
Exelixis Clinical Site #3 RECRUITING Charlottesville Virginia 22903 United States Details
Exelixis Clinical Site #13 RECRUITING Fairfax Virginia 22031 United States Details
Exelixis Clinical Site #2 RECRUITING San Juan 00909 Puerto Rico Details
Exelixis Clinical Site # 4 RECRUITING San Juan 00927 Puerto Rico Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field